These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 28490629)

  • 1. Pharmacological targeting of RAD6 enzyme-mediated translesion synthesis overcomes resistance to platinum-based drugs.
    Sanders MA; Haynes B; Nangia-Makker P; Polin LA; Shekhar MP
    J Biol Chem; 2017 Jun; 292(25):10347-10363. PubMed ID: 28490629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RAD6B is a major mediator of triple negative breast cancer cisplatin resistance: Regulation of translesion synthesis/Fanconi anemia crosstalk and BRCA1 independence.
    Haynes B; Gajan A; Nangia-Makker P; Shekhar MP
    Biochim Biophys Acta Mol Basis Dis; 2020 Jan; 1866(1):165561. PubMed ID: 31639439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel inhibitors of Rad6 ubiquitin conjugating enzyme: design, synthesis, identification, and functional characterization.
    Sanders MA; Brahemi G; Nangia-Makker P; Balan V; Morelli M; Kothayer H; Westwell AD; Shekhar MPV
    Mol Cancer Ther; 2013 Apr; 12(4):373-83. PubMed ID: 23339190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nano-delivery of
    Saadat N; Liu F; Haynes B; Nangia-Makker P; Bao X; Li J; Polin LA; Gupta S; Mao G; Shekhar MP
    Mol Cancer Ther; 2018 Dec; 17(12):2586-2597. PubMed ID: 30242094
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rad6/Rad18 Competes with DNA Polymerases η and δ for PCNA Encircling DNA.
    Li M; Larsen L; Hedglin M
    Biochemistry; 2020 Feb; 59(4):407-416. PubMed ID: 31887036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gold nanoparticle conjugated Rad6 inhibitor induces cell death in triple negative breast cancer cells by inducing mitochondrial dysfunction and PARP-1 hyperactivation: Synthesis and characterization.
    Haynes B; Zhang Y; Liu F; Li J; Petit S; Kothayer H; Bao X; Westwell AD; Mao G; Shekhar MPV
    Nanomedicine; 2016 Apr; 12(3):745-757. PubMed ID: 26563438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage.
    Haynes BM; Cunningham K; Shekhar MPV
    BMC Cancer; 2022 Oct; 22(1):1073. PubMed ID: 36258187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RAD6B overexpression confers chemoresistance: RAD6 expression during cell cycle and its redistribution to chromatin during DNA damage-induced response.
    Lyakhovich A; Shekhar MP
    Oncogene; 2004 Apr; 23(17):3097-106. PubMed ID: 14981545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human colon cancer cells surviving high doses of cisplatin or oxaliplatin in vitro are not defective in DNA mismatch repair proteins.
    Sergent C; Franco N; Chapusot C; Lizard-Nacol S; Isambert N; Correia M; Chauffert B
    Cancer Chemother Pharmacol; 2002 Jun; 49(6):445-52. PubMed ID: 12107548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts.
    Vaisman A; Varchenko M; Umar A; Kunkel TA; Risinger JI; Barrett JC; Hamilton TC; Chaney SG
    Cancer Res; 1998 Aug; 58(16):3579-85. PubMed ID: 9721864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination.
    Tentori L; Muzi A; Dorio AS; Dolci S; Campolo F; Vernole P; Lacal PM; Praz F; Graziani G
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):117-25. PubMed ID: 23636450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specificity of platinum-DNA adduct repair.
    Chaney SG; Vaisman A
    J Inorg Biochem; 1999 Oct; 77(1-2):71-81. PubMed ID: 10626357
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of Rad6/Rad18 Activity During DNA Damage Tolerance.
    Hedglin M; Benkovic SJ
    Annu Rev Biophys; 2015; 44():207-28. PubMed ID: 26098514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Crosstalk between translesion synthesis, Fanconi anemia network, and homologous recombination repair pathways in interstrand DNA crosslink repair and development of chemoresistance.
    Haynes B; Saadat N; Myung B; Shekhar MP
    Mutat Res Rev Mutat Res; 2015; 763():258-66. PubMed ID: 25795124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers.
    Raymond E; Buquet-Fagot C; Djelloul S; Mester J; Cvitkovic E; Allain P; Louvet C; Gespach C
    Anticancer Drugs; 1997 Oct; 8(9):876-85. PubMed ID: 9402315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and mechanistic studies of polymerase η bypass of phenanthriplatin DNA damage.
    Gregory MT; Park GY; Johnstone TC; Lee YS; Yang W; Lippard SJ
    Proc Natl Acad Sci U S A; 2014 Jun; 111(25):9133-8. PubMed ID: 24927576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Replication protein A dynamically regulates monoubiquitination of proliferating cell nuclear antigen.
    Hedglin M; Aitha M; Pedley A; Benkovic SJ
    J Biol Chem; 2019 Mar; 294(13):5157-5168. PubMed ID: 30700555
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Supramolecular complex formation between Rad6 and proteins of the p53 pathway during DNA damage-induced response.
    Lyakhovich A; Shekhar MP
    Mol Cell Biol; 2003 Apr; 23(7):2463-75. PubMed ID: 12640129
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NBS1 recruits RAD18 via a RAD6-like domain and regulates Pol η-dependent translesion DNA synthesis.
    Yanagihara H; Kobayashi J; Tateishi S; Kato A; Matsuura S; Tauchi H; Yamada K; Takezawa J; Sugasawa K; Masutani C; Hanaoka F; Weemaes CM; Mori T; Zou L; Komatsu K
    Mol Cell; 2011 Sep; 43(5):788-97. PubMed ID: 21884979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.